Drugs / Lu AG09222
Lu AG09222
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06578585 | Sep 2024 → Jul 2025 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05304910 | Mar → Oct 2022 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05126316 | Nov 2021 → Jul 2022 | allergic rhinitis | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04976309 | Jul → Sep 2021 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06323928 | Apr 2024 → Jan 2026 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT05133323 | Nov 2021 → Jan 2023 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02158221 Comparator | Jun → Nov 2014 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AG09222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05133323 ↗ |
| Known as | PACAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02158221 ↗ |
| Known as | Pituitary adenylate cyclase-activating polypeptide | “Pituitary adenylate cyclase-activating polypeptide (PACAP)” NCT02158221 ↗ |
| Action | Inhibit | “Lu AG09222 inhibited PACAP38-induced cephalic vasodilation and increases in heart rate, and reduced concomitant headache.” PMID 37231350 ↗ May 2023 |
| Modality | Peptide | “PACAP is a neuropeptide” NCT02158221 ↗ |
| Route | Intravenous | “PACAP intravenous infusion 1.5 microgram/min for 20 min” NCT02158221 ↗ |